Home >> Marketplace Archives >> ABL adds Aushon Cira platform, 12/17

ABL adds Aushon Cira platform, 12/17

Print Friendly, PDF & Email

 

December 2017—Aushon BioSystems and ABL announced that ABL has adopted the Cira platform for multiplex and ultrasensitive biomarker analysis. ABL will offer this proprietary technology as a new addition to its service offerings in support of pharmaceutical and clinical research clients.

“Implementing Aushon’s Cira platform in our GCLP clinical laboratory enables us to look deeper at biomarkers of interest, previously found to be undetectable or inconsistently quantitated by other methods. This opens exciting opportunities for ABL in evaluation of low abundance proteins, especially in a restricted volume or dilute sample. Aushon’s sensitivity and nondestructive readout is particularly useful in exploring minute changes in cytokines and other soluble biomarkers to determine possible correlates of protection, inflammatory responses, and novel signaling pathways activated in various matrices,” Franck Lemiale, PhD, PharmD, senior director of immunobiology at ABL, said in a statement.

ABL, 301-881-5600

Aushon Biosystems, 978-436-6400

X